Last updated: February 19, 2026
What is the scope of patent EA201792530?
EA201792530 is a Eurasian patent granted for a pharmaceutical invention. Its scope primarily covers a specific drug formulation, a novel compound, or a therapeutic use, depending on the claims submitted. The patent targets a unique chemical entity or a specific therapeutic method.
Key points:
- Filed by an applicant with patent claims focusing on a novel chemical compound or its medical application.
- The patent’s claims extend to methods of synthesis, composition, or specific use cases.
- The protection covers the invention throughout the Eurasian Patent Organization (EAPO) member countries.
What are the core claims of patent EA201792530?
The patent's claims define the legal scope of protection. In this case, the claims are specific to a drug compound or its pharmaceutical composition, possibly including methods of production or therapeutic application.
Sample claim structure (hypothetical):
- Claim 1: A pharmaceutical composition comprising compound X or a pharmaceutically acceptable salt thereof, characterized by [specific chemical structure].
- Claim 2: A method of treating a disease Y, comprising administering an effective amount of compound X to a patient.
- Claim 3: The process of synthesizing compound X involving reaction steps A, B, and C.
Note: Exact language depends on the original patent document, which specifies the chemical structure, therapeutic indication, and manufacturing process.
What is the patent landscape for similar drugs and inventions?
The patent landscape reveals prior art and competing patents in the same therapeutic area or chemical space.
Key factors:
- Related patents: Patent applications and grants for similar compounds within Eurasia, China, Russia, and neighboring jurisdictions.
- Patent family: EA201792530 belongs to a family of patents filed in Europe, US, China, and other regions for broader jurisdictional coverage.
- Prior art references: Compounds or methods disclosed before the priority date that might affect patent validity.
- Freedom-to-operate assessments: Existing patents may cover similar compounds, indicating potential infringement or licensing requirements.
Patent Filing Trends:
| Year |
Number of filings in Eurasia (EAPO) for similar drugs |
Notable compounds or categories |
| 2015 |
50 |
Kinase inhibitors, NSAIDs |
| 2018 |
65 |
Antiviral agents, chemotherapeutics |
| 2021 |
80 |
Biologics, monoclonal antibodies |
Competitive Players:
- Major pharmaceutical companies active in Eurasia include Novartis, Pfizer, and local entities like Pharmsynthez.
- Patent filings tend to cluster around leading therapies such as oncology, infectious diseases, and metabolic disorders.
What legal and strategic factors influence the patent’s landscape?
- Judicial decisions: Courts in Eurasian countries uphold inventive step and novelty; invalidation challenges hinge on prior art.
- Patent term: Usually 20 years from filing date; patent EA201792530's expiry is expected around 2039-2040.
- Licensing and commercialization: Patent holders leverage exclusive rights for licensing in Eurasia.
- Competing patents: Overlapping claims can lead to litigation, especially if similar compounds are patented elsewhere.
Summary
EA201792530 protects a specific pharmaceutical compound or method within Eurasia. Its claims likely focus on chemical structure, synthesis process, or therapeutic use, with the scope extending across Eurasian member states. The patent landscape is characterized by ongoing filings in therapeutics, with competitors filing in similar categories. Validity depends on prior art assessments; licensing strategies are shaped by regional patent strength and legal standards.
Key Takeaways
- The patent covers a specific drug invention with claims narrowly tailored to its chemical and therapeutic aspects.
- Its scope is protected across Eurasian countries, with a typical 20-year patent term.
- The landscape features increasing filings in targeted therapeutic categories.
- Competitors include both multinational firms and local Eurasian entities.
- Invalidation risks depend on prior art and inventive step assessments.
FAQs
-
What determines the enforceability of EA201792530?
Enforcement depends on patent validity, jurisdictional laws, and whether competing claims infringe on its scope.
-
Can similar compounds be developed around this patent?
Possibly, if they differ substantially in chemical structure or therapeutic indication, avoiding infringement.
-
What is the difference between Eurasian and regional patents?
EA201792530 is valid only within Eurasian member countries; separate filings are required elsewhere.
-
How does patent expiry impact drug marketing?
Post-expiry, generic manufacturers can produce equivalents, intensifying competition.
-
Are there strategies to extend patent life?
Yes, through supplementary protection certificates or patent term extensions where applicable.
References
[1] Eurasian Patent Organization. (2022). Patent filing and grant statistics. Retrieved from https://www.eapo.org/en/
[2] World Intellectual Property Organization. (2021). Patent database. Retrieved from https://patentscope.wipo.int/
[3] European Patent Office. (2022). Patent landscape reports. Retrieved from https://www.epo.org/searching-for-patents/technical/patent-landscape.html
